









市场行情
/
股票
/
nasdaq-mgtx
/

MeiraGTx Holdings PLC

MGTX

7.970USD

-0.300-3.63%

收盘 12/26, 16:00（美东）报价延迟15分钟

641.42M总市值

亏损市盈率 TTM



MeiraGTx Holdings PLC

7.970

-0.300-3.63%

概览公司财务分析

概览

公司

财务

分析

关于 MeiraGTx Holdings PLC 公司

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

MeiraGTx Holdings PLC简介



公司代码MGTX

公司名称MeiraGTx Holdings PLC

上市日期Jun 08, 2018

CEOForbes (Alexandria)

员工数量381

证券类型Ordinary Share

年结日Jun 08

公司地址655 Third Avenue

城市NEW YORK

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编10017

电话16468607985

网址https://meiragtx.com/

公司代码MGTX

上市日期Jun 08, 2018

CEOForbes (Alexandria)

MeiraGTx Holdings PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Alexandria Forbes, Ph.D.

President, Chief Executive Officer, Director

1.31M

-3.49%

Mr. Richard Giroux

Chief Financial Officer, Chief Operating Officer

919.65K

-2.54%

Dr. Stuart Naylor, Ph.D.

Chief Development Officer

623.29K

Mr. Thomas E. Shenk, Ph.D.

Independent Director

157.48K

Mr. Robert K. Zeldin, M.D.

Chief Medical Officer

136.52K

+7.14%

Dr. Keith R. Harris, Ph.D.

Independent Chairman of the Board

125.00K

+150.00%

Mr. Robert J. Wollin, J.D.

General Counsel, Secretary

26.15K

-16.05%

Ms. Ellen Hukkelhoven, Ph.D.

Independent Director

Ms. Nicole Seligman

Independent Director

Mr. Neil F. J. (Lord) Mendoza

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Alexandria Forbes, Ph.D.

President, Chief Executive Officer, Director

1.31M

-3.49%

Mr. Richard Giroux

Chief Financial Officer, Chief Operating Officer

919.65K

-2.54%

Dr. Stuart Naylor, Ph.D.

Chief Development Officer

623.29K

Mr. Thomas E. Shenk, Ph.D.

Independent Director

157.48K

Mr. Robert K. Zeldin, M.D.

Chief Medical Officer

136.52K

+7.14%

Dr. Keith R. Harris, Ph.D.

Independent Chairman of the Board

125.00K

+150.00%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Perceptive Advisors LLC

15.69%

Sanofi SA

15.15%

Johnson & Johnson Innovation-JJDC, Inc.

8.25%

Adage Capital Management, L.P.

5.20%

Prosight Capital

5.08%

其他

50.63%

持股股东

占比

Perceptive Advisors LLC

15.69%

Sanofi SA

15.15%

Johnson & Johnson Innovation-JJDC, Inc.

8.25%

Adage Capital Management, L.P.

5.20%

Prosight Capital

5.08%

其他

50.63%

股东类型

持股股东

占比

Hedge Fund

26.94%

Corporation

16.02%

Private Equity

15.69%

Venture Capital

8.29%

Investment Advisor

7.12%

Investment Advisor/Hedge Fund

4.38%

Individual Investor

4.17%

Research Firm

2.26%

Pension Fund

0.09%

其他

15.04%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

228

52.30M

65.02%

+2.51M

2025Q2

231

67.71M

84.26%

+4.10M

2025Q1

245

80.15M

99.86%

+3.86M

2024Q4

246

77.41M

99.87%

+22.10M

2024Q3

250

64.74M

84.14%

+9.72M

2024Q2

251

52.33M

80.03%

+4.22M

2024Q1

254

51.24M

78.85%

+2.58M

2023Q4

253

50.76M

80.27%

+3.66M

2023Q3

255

41.86M

71.40%

-5.70M

2023Q2

256

41.99M

71.79%

-2.93M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Perceptive Advisors LLC

12.63M

15.69%

+45.00K

+0.36%

Jun 30, 2025

Sanofi SA

12.20M

15.16%

Jun 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

6.64M

8.26%

Jun 30, 2025

Adage Capital Management, L.P.

6.03M

7.5%

+400.00K

+7.10%

Jun 30, 2025

Prosight Capital

4.59M

5.7%

+895.88K

+24.27%

Jun 30, 2025

Rubric Capital Management LP

3.73M

4.63%

+1.95M

+109.78%

Jun 30, 2025

683 Capital Management LLC

2.69M

3.34%

+115.00K

+4.47%

Jun 30, 2025

Millennium Management LLC

785.18K

0.98%

+785.18K

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.48M

3.09%

-243.04K

-8.91%

Jun 30, 2025

J. Goldman & Co., L.P.

2.04M

2.54%

+885.81K

+76.44%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

iShares Micro-Cap ETF

0.07%

ProShares Ultra Nasdaq Biotechnology

0.07%

Invesco Nasdaq Biotechnology ETF

0.07%

Goldman Sachs Innovate Equity ETF

0.06%

Vanguard US Momentum Factor ETF

0.04%

iShares Biotechnology ETF

0.04%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Russell 2000 Growth ETF

0.02%

SPDR S&P International Small Cap ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

iShares Micro-Cap ETF

占比0.07%

ProShares Ultra Nasdaq Biotechnology

占比0.07%

Invesco Nasdaq Biotechnology ETF

占比0.07%

Goldman Sachs Innovate Equity ETF

占比0.06%

Vanguard US Momentum Factor ETF

占比0.04%

iShares Biotechnology ETF

占比0.04%

Invesco RAFI US 1500 Small-Mid ETF

占比0.02%

iShares Russell 2000 Growth ETF

占比0.02%

SPDR S&P International Small Cap ETF

占比0.02%

iShares Russell 2000 Value ETF

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

MeiraGTx Holdings PLC的前五大股东是谁？



MeiraGTx Holdings PLC 的前五大股东如下：
Perceptive Advisors LLC持有股份：12.63M，占总股份比例：15.69%。
Sanofi SA持有股份：12.20M，占总股份比例：15.16%。
Johnson & Johnson Innovation-JJDC, Inc.持有股份：6.64M，占总股份比例：8.26%。
Adage Capital Management, L.P.持有股份：6.03M，占总股份比例：7.50%。
Prosight Capital持有股份：4.59M，占总股份比例：5.70%。